Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol

Bo Jan Noordman   ¹ , MD ;   Joel Shapiro   ¹ , MD ;   Manon CW Spaander   ² , MD,PhD ;   Kausilia K Krishnadath   ³ , MD,PhD ;   Hanneke WM van Laarhoven   ⁴ , MD,PhD ;   Mark I van Berge Henegouwen   ⁵ , MD,PhD ;   Grard AP Nieuwenhuijzen   ⁶ , MD,PhD ;   Richard van Hillegersberg   ⁷ , MD,PhD ;   Meindert N Sosef   ⁸ , MD,PhD ;   Ewout W Steyerberg   ⁹ , MD,PhD ;   Bas PL Wijnhoven   ¹ , MD,PhD ;   J Jan B van Lanschot   ¹ , MD,PhD

¹ Erasmus MC - University Medical Center Rotterdam, Department of Surgery, Rotterdam, The Netherlands

² Erasmus MC - University Medical Center Rotterdam, Department of Gastroenterology, Rotterdam, The Netherlands

³ Academic Medical Center, Department of Gastroenterology, Amsterdam, The Netherlands

⁴ Academic Medical Center, Department of Medical Oncology, Amsterdam, The Netherlands

⁵ Academic Medical Center, Department of Surgery, Amsterdam, The Netherlands

⁶ Catharina Cancer Center, Department of Surgery, Eindhoven, The Netherlands

⁷ University Medical Center, Department of Surgery, Utrecht, The Netherlands

⁸ Atrium Medical Center, Department of Surgery, Heerlen, The Netherlands

⁹ Erasmus MC - University Medical Center Rotterdam, Department of Public Health, Rotterdam, The Netherlands